• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    4/10/24 10:06:09 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 SEER INC CLASS A COMMON STOCK Cusip #81578P106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #81578P106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 702,566 Item 6: 0 Item 7: 706,599 Item 8: 0 Item 9: 706,599 Item 11: 1.163% Item 12: HC Cusip #81578P106 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 706,599 Item 8: 0 Item 9: 706,599 Item 11: 1.163% Item 12: IN Item 1(a). Name of Issuer: SEER INC Item 1(b). Address of Issuer's Principal Executive Offices: 3800 BRIDGE PARKWAY, SUITE 102 REDWOOD CITY, CA 94065 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: CLASS A COMMON STOCK Item 2(e). CUSIP Number: 81578P106 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 706,599 (b) Percent of Class: 1.163% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 706,599 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of SEER INC. No one other person's interest in the CLASS A COMMON STOCK of SEER INC is more than five percent of the total outstanding CLASS A COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. April 9, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on April 9, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the CLASS A COMMON STOCK of SEER INC at March 28, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $SEER alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Seer Inc.

      SC 13G/A - Seer, Inc. (0001726445) (Subject)

      8/2/24 6:33:25 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Seer Inc.

      SC 13G/A - Seer, Inc. (0001726445) (Subject)

      7/8/24 4:32:39 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Seer Inc. (Amendment)

      SC 13G/A - Seer, Inc. (0001726445) (Subject)

      4/10/24 10:06:09 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Seer Inc.

      DEFA14A - Seer, Inc. (0001726445) (Filer)

      5/28/25 4:21:27 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Seer Inc.

      DEF 14A - Seer, Inc. (0001726445) (Filer)

      5/28/25 4:19:40 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Seer Inc.

      SCHEDULE 13G/A - Seer, Inc. (0001726445) (Subject)

      5/14/25 4:01:18 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    See more
    • Seer Appoints Nicolas Roelofs to its Board of Directors

      REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

      8/14/24 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer

      REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina. "I'm thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented

      3/16/22 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Appoints Meeta Gulyani to its Board of Directors

      REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Meeta Gulyani to serve on its Board of Directors. Ms. Gulyani is currently Executive Vice President, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, a global science and technology company, which operates as MilliporeSigma in the U.S. and Canada. "Meeta is a seasoned life sciences and pharma leader with global experience across markets, including Asia, an important market for Seer, and we are really pleased to welcome Me

      11/29/21 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan resumed coverage on Seer with a new price target

      JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

      7/5/23 7:25:16 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer downgraded by BofA Securities with a new price target

      BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

      1/4/23 9:03:59 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer downgraded by JP Morgan with a new price target

      JP Morgan downgraded Seer from Overweight to Neutral and set a new price target of $12.00 from $20.00 previously

      8/11/22 6:17:02 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT & CFO Horn David R. sold $14,028 worth of shares (6,760 units at $2.08), decreasing direct ownership by 2% to 443,629 units (SEC Form 4)

      4 - Seer, Inc. (0001726445) (Issuer)

      5/22/25 4:13:53 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CEO AND CHAIR Farokhzad Omid sold $69,854 worth of shares (33,663 units at $2.08), decreasing direct ownership by 3% to 1,306,060 units (SEC Form 4)

      4 - Seer, Inc. (0001726445) (Issuer)

      5/22/25 4:10:49 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CFO Horn David R. covered exercise/tax liability with 26,572 shares, decreasing direct ownership by 6% to 450,389 units (SEC Form 4)

      4 - Seer, Inc. (0001726445) (Issuer)

      2/20/25 4:13:50 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

      REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics. Seer's newest innovation, debuting at the upcoming American Society for Mass Spectrometry (ASMS) annual conference in Baltimore, MD, overcomes the challenges of large-scale proteomic studies that had been hindered by limited throughput and prohibitive costs. It significantly enhances the flagship Proteograph Product Suit

      5/29/25 7:00:00 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

      REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025Secured a significant contract with a new customer to run a 10,000-sample study in collaboration with Discovery Life SciencesAccelerated third-party validation of platform through increasing number of customer publications, webinars, preprints and reviewsEnded the quarter with approximately $285 million of cash, cash equivalents and investments "We are proud of our

      5/13/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer to Report First Quarter 2025 Financial Results on May 13, 2025

      REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to the

      4/24/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Financials

    Live finance-specific insights

    See more
    • Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

      REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025Secured a significant contract with a new customer to run a 10,000-sample study in collaboration with Discovery Life SciencesAccelerated third-party validation of platform through increasing number of customer publications, webinars, preprints and reviewsEnded the quarter with approximately $285 million of cash, cash equivalents and investments "We are proud of our

      5/13/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer to Report First Quarter 2025 Financial Results on May 13, 2025

      REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to the

      4/24/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook

      REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Achieved revenue of $4.0 million for the fourth quarter of 2024 and $14.2 million for the full year 2024Shipped 10 instruments during 2024, bringing cumulative instruments shipped to 72 as of December 31, 2024Launched a new product application for the Proteograph XT workflow, specifically designed for cell lysis proteomics, unlocking unprecedented depth in intracellular proteomicsShowcased new findings and a

      2/27/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials